patients taking isradipine (DynaCirc) have a higher risk of angina
The several studies about calcium blockers over the last year have raised huge questions about their safety.
That's why there's so much interest in a brand-new study in JAMA that suggests patients taking isradipine (DynaCirc) have a higher risk of angina...and other adverse events.
These unexpected results come from a study that was designed for a DIFFERENT purpose...to see if either isradipine or HCTZ slows the development of atherosclerosis.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote